Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives

Filgotinib is an orally administered, preferential Janus kinase (JAK) inhibitor indicated for the treatment of moderate-to-severe rheumatoid arthritis (RA). The short-term safety, efficacy, and patient-reported outcomes (PROs) with filgotinib from Phase 2b/3 clinical trials (DARWIN 1 and 2; FINCH 1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Genovese, Mark C, Matsushima, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563783/
https://www.ncbi.nlm.nih.gov/pubmed/37822545
http://dx.doi.org/10.2147/PPA.S417677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563783/
https://www.ncbi.nlm.nih.gov/pubmed/37822545
http://dx.doi.org/10.2147/PPA.S417677

Ejemplares similares